Overall, our results suggest that PTPN6 and activated STAT3 can be developed as prognostic markers, and the combination of DNMTi and JAK3 inhibitors as a novel treatment for patients with PTCL subtypes. The gene discussed is JAK3; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.